This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.


ELIQUIS® (apixaban) resources for
healthcare professionals

ELIQUIS (apixaban): an oral, direct factor Xa inhibitor indicated for:

  • Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II)1
  • Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults1
  • Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery1

Checklist to use when prescribing ELIQUIS to patients for stroke prevention in NVAF

To download and print, click here

Checklist to use when prescribing ELIQUIS to patients with DVT / PE

To download and print, click here

Checklist to use when prescribing ELIQUIS to patients with NVAF switching from warfarin

To download and print, click here

FOOTNOTES

DVT = Deep Vein Thrombosis   NVAF = Non-Valvular Atrial Fibrillation   NYHA = New York Heart Association   PE = Pulmonary Embolism   
TIA = Transient Ischaemic Attack

REFERENCE

  1. ELIQUIS® (apixaban) Summary of Product Characteristics. Available at www.medicines.org.uk.